Biomea Fusion

Biomea Fusion is a clinical-stage biopharmaceutical company focused on developing and commercializing irreversible small molecule drugs to treat genetically defined cancers and metabolic diseases. They generate revenue primarily through the development and potential future sales of their proprietary therapies. Founded in 2017, Biomea Fusion leverages its proprietary FUSION™ System platform to create targeted therapies, aiming to provide more effective and durable treatments. The company’s lead product candidate, BMF-219, is an irreversible menin inhibitor currently in clinical trials for various cancers.

Recent Posts by Biomea Fusion

1-9 of 9